Evidence map›Paper›PMID 31091767›Full record

ReviewCancers2019

Control of Tyrosine Kinase Signalling by Small Adaptors in Colorectal Cancer.

Rudy Mevizou, Audrey Sirvent, Serge Roche

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rudy MevizouCRBM, CNRS, Univ. Montpellier, "Equipe labellisée Ligue Contre le Cancer", F-34000 Montpellier, France. rudy.mevizou@crbm.cnrs.fr.
Audrey SirventCRBM, CNRS, Univ. Montpellier, "Equipe labellisée Ligue Contre le Cancer", F-34000 Montpellier, France. audrey.sirvent@crbm.cnrs.fr.ORCID 0000-0003-4555-6312
Serge RocheCRBM, CNRS, Univ. Montpellier, "Equipe labellisée Ligue Contre le Cancer", F-34000 Montpellier, France. serge.roche@crbm.cnrs.fr.ORCID 0000-0003-3413-3859
Centre National de la Recherche Scientifique · FR

Funding

Institut National Du Cancer INCa-DGOS-Inserm 6045Ligue Contre le Cancer equipe labellisée LIGUE 2017
6 · The paper itself

Abstract

Tyrosine kinases (TKs) phosphorylate proteins on tyrosine residues as an intracellular signalling mechanism to coordinate intestinal epithelial cell communication and fate decision. Deregulation of their activity is ultimately connected with carcinogenesis. In colorectal cancer (CRC), it is still unclear how aberrant TK activities contribute to tumour formation because TK-encoding genes are not frequently mutated in this cancer. In vertebrates, several TKs are under the control of small adaptor proteins with potential important physiopathological roles. For instance, they can exert tumour suppressor functions in human cancer by targeting several components of the oncogenic TK signalling cascades. Here, we review how the Src-like adaptor protein (SLAP) and the suppressor of cytokine signalling (SOCS) adaptor proteins regulate the SRC and the Janus kinase (JAK) oncogenic pathways, respectively, and how their loss of function in the intestinal epithelium may influence tumour formation. We also discuss the potential therapeutic value of these adaptors in CRC.

Indexed as

cell signallingcolorectal cancersmall adaptor proteinstargeted therapytyrosine kinase

Identifiers

PMID31091767
PMCPMC6562749
OpenAlexW2945784542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.